Cellectar Biosciences (NASDAQ:CLRB) Stock Price Crosses Below 200 Day Moving Average – What’s Next?

Posted by George Bondi on Aug 1st, 2026

Cellectar Biosciences, Inc. (NASDAQ:CLRB – Get Free Report) crossed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $2.94 and traded as low as $2.47. Cellectar Biosciences shares last traded at $2.53, with a volume of 30,164 shares changing hands.

Analyst Ratings Changes

Several analysts have issued reports on CLRB shares. Brookline Capital Markets upgraded Cellectar Biosciences to a “strong-buy” rating in a research note on Sunday, July 12th. Wall Street Zen raised Cellectar Biosciences to a “hold” rating in a report on Saturday, June 20th. Weiss Ratings restated a “sell (e+)” rating on shares of Cellectar Biosciences in a research note on Friday, July 17th. LADENBURG THALM/SH SH assumed coverage on shares of Cellectar Biosciences in a report on Friday, May 15th. They set a “buy” rating on the stock. Finally, Roth Capital reiterated a “buy” rating and set a $11.00 target price on shares of Cellectar Biosciences in a research report on Tuesday, May 5th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $11.00.

View Our Latest Stock Report on CLRB

Cellectar Biosciences Stock Up 1.6%

The firm has a 50-day simple moving average of $2.64 and a 200-day simple moving average of $2.94. The stock has a market cap of $20.53 million, a PE ratio of -0.39 and a beta of 0.55.

Cellectar Biosciences (NASDAQ:CLRB – Get Free Report) last announced its quarterly earnings results on Thursday, May 14th. The biopharmaceutical company reported ($1.33) earnings per share for the quarter, beating the consensus estimate of ($1.88) by $0.55. On average, research analysts expect that Cellectar Biosciences, Inc. will post -2.34 earnings per share for the current year.

Hedge Funds Weigh In On Cellectar Biosciences

A number of large investors have recently modified their holdings of CLRB. DRW Securities LLC increased its holdings in Cellectar Biosciences by 114.2% during the 4th quarter. DRW Securities LLC now owns 45,190 shares of the biopharmaceutical company’s stock worth $133,000 after acquiring an additional 24,089 shares during the period. Geode Capital Management LLC boosted its holdings in Cellectar Biosciences by 15.0% in the 4th quarter. Geode Capital Management LLC now owns 28,636 shares of the biopharmaceutical company’s stock valued at $84,000 after purchasing an additional 3,744 shares during the period. Citadel Advisors LLC bought a new position in Cellectar Biosciences in the 3rd quarter valued at $104,000. Dimensional Fund Advisors LP purchased a new position in shares of Cellectar Biosciences during the 3rd quarter valued at $73,000. Finally, Bank of America Corp DE grew its position in shares of Cellectar Biosciences by 25.3% during the 4th quarter. Bank of America Corp DE now owns 206,783 shares of the biopharmaceutical company’s stock valued at $62,000 after purchasing an additional 41,704 shares in the last quarter. 16.41% of the stock is currently owned by institutional investors.

About Cellectar Biosciences

(Get Free Report)

Cellectar Biosciences, Inc is a clinical‐stage biopharmaceutical company focused on the development of targeted cancer therapies and imaging agents. The company’s proprietary phospholipid drug conjugate (PDC) technology platform is designed to selectively deliver therapeutic and diagnostic payloads to malignant cells while sparing healthy tissue. Through its PDC approach, Cellectar aims to improve the efficacy and safety profile of traditional treatments like chemotherapy and radiotherapy.

Its lead therapeutic candidate, CLR 131, is a radioisotope‐labeled PDC being evaluated in Phase II clinical trials for relapsed or refractory B‐cell malignancies, including multiple myeloma and non‐Hodgkin lymphoma.